Published summary: 2026-03-07
Where the evidence converges
Largest-ever meta-analysis (183M patients) found cannabis use significantly associated with stroke risk but not heart attack risk — though observational data can't prove causation
Strong evidence · 4 studies
All included studies were observational — the association between cannabis and stroke cannot be confirmed as causal. Residual confounding is a major concern: cannabis users may differ from non-users i
Meta-analysis of 81 million participants found cannabis use associated with 71% higher atrial arrhythmia risk, with concurrent drug use and legal country status further increasing risk
Strong evidence · 4 studies
All observational studies; heterogeneity in cannabis use definitions; cannot determine dose-response; confounding by tobacco and other substances; no teenage population data.
Meta-analysis of 100+ million participants plus genetic analysis confirms cannabis use disorder is causally linked to stroke, particularly large artery stroke
Strong evidence · 4 studies
Observational meta-analysis showed heterogeneity and small-study effects for cannabis. Mendelian randomization assumes certain conditions (no pleiotropy, relevant instruments) that may not be perfectl
Where questions remain
A 1978 medical review identified cannabis as promising for glaucoma and asthma but flagged cardiovascular risks during exercise and preliminary concerns about lung and immune effects
Moderate evidence · 34 studies
As a narrative review from 1978, it reflects limited evidence available at that time. The cannabis landscape has changed dramatically in terms of product potency, consumption methods, and the volume o
A major 1986 pharmacological review found cannabis's greatest health concern was its impact on youth development, while finding no proven brain damage and limited physical dependence in adults
Moderate evidence · 34 studies
Reflects evidence available through the mid-1980s. Cannabis potency, usage patterns, and the volume of research have all changed dramatically. The review's reassurance about lung effects preceded mode
Review finding cannabis increases heart rate with rapid tolerance development, poses minimal risk for young healthy users but significant risks for people with existing cardiovascular disease
Moderate evidence · 34 studies
As a narrative review, the evidence was synthesized without systematic methodology. Most data came from studies in young, healthy subjects and may not apply to older or medically compromised populatio
Review comparing cardiovascular effects of five substance classes, finding cannabis posed fewer heart risks than opiates, amphetamines, or alcohol, though cognitive effects were noted
Moderate evidence · 34 studies
The review covered five substance classes in a single paper, limiting depth on each. The cardiovascular effects of cannabis were not extensively detailed in the abstract. The cognitive effects mention
Research gaps
- Only 7 randomized controlled trials exist out of 213 studies — most evidence is observational or from reviews.
- Long-term prospective studies tracking outcomes over 5+ years are largely absent from the literature.
- Research on diverse populations (different ages, ethnicities, and medical backgrounds) remains limited.
Key studies
Cannabis, Cocaine, and Amphetamines All Linked to Higher Stroke Risk in Major Analysis
The Mendelian randomization component is crucial because it uses genetic variation to approximate a natural experiment, providing stronger evidence for causation than observational studies alone. Finding that cannabis use disorder is genetically linked to large artery stroke is a significant public
Cannabis use was associated with a 71% increased risk of atrial arrhythmias
As cannabis use expands globally, the cardiovascular risk profile is becoming clearer, and atrial arrhythmias represent a serious but potentially underrecognized consequence.
Cannabis and Heart Attack/Stroke Risk: A 183-Million-Patient Meta-Analysis Finds Stroke Risk but Not Heart Attack Risk
This is the largest meta-analysis of cannabis and cardiovascular risk ever conducted. With over 183 million patients, it has statistical power that individual studies lack. The finding that stroke risk is elevated while heart attack risk is not suggests cannabis may affect the cardiovascular system
JAMA's Comprehensive Review of What Cannabis Can and Can't Treat
A JAMA review represents the medical establishment's current consensus position. The fact that it was published in 2026 — years after most US states legalized some form of cannabis — signals that the medical community is still working to align clinical practice with evidence. The review's distinctio
Meta-Analysis Finds Cannabis Users Have Twice the Risk of Ischemic Stroke
Ischemic stroke among young adults is increasing globally, paralleling rising cannabis use. This meta-analysis provides the strongest pooled evidence to date that cannabis use approximately doubles stroke risk, a finding with particular relevance as legalization expands and cannabis is increasingly
Cannabis Users Had 48% Higher Risk of Cardiovascular Events in Large Meta-Analysis
Whether cannabis causes cardiovascular disease has been debated for years. This meta-analysis of nearly 1.9 million people provides the strongest pooled estimate to date, showing a significant association with composite cardiovascular events even if individual endpoints fall short of significance.
How the research developed
Pre-2000
6 studies published. Includes 2 RCTs.
2000–2009
9 studies published. Predominantly observational and review studies.
2010–2014
13 studies published. Predominantly observational and review studies.
2015–2019
43 studies published. Includes 1 RCTs, 1 strong-evidence studies.
2020–present
142 studies published. Includes 7 meta-analyses, 4 RCTs, 20 strong-evidence studies.
How this summary was assembled
This consensus synthesizes 213 peer-reviewed studies: 7 meta-analyses (3%), 7 randomized controlled trials (3%), 36 observational studies (17%), 54 reviews (25%), 43 case studies (20%), 66 other study types (31%). Studies span from the earliest available research through 2025. Evidence strength ratings reflect study design, sample size, and replication across multiple research groups.
These counts describe the source summary at publication. They may differ from the current library.